“Based on the current evidence from randomized controlled trials, the DOH agrees with the COVID-19 Living CPG Reviewers and does not recommend the use of Ivermectin for the treatment of COVID-19,” the Department of Health and Food and Drug Administration said in a statement.
Health officials noted that studies from the Philippine COVID-19 Living CPG Reviewers of randomized controlled trials showed that: 2. Ivermectin was NOT ASSOCIATED with a definite benefit of other clinically important outcomes such as clinical improvement at Day 6-10, clinical deterioration, and need for mechanical ventilation;
4. The rate of hospitalization discharge DID NOT DIFFER SIGNIFICANTLY between the Ivermectin group and the placebo group.“Moreover, we, the DOH and FDA, as well as Malacañan put the safety of Filipinos first before allowing unproven and uncertified medicines in the country,” they added.
Source: Healthcare Press (healthcarepress.net)